NEW YORK (GenomeWeb News) – CompanionDx and GenomOncology will develop a series of next-generation sequencing-based assays for cancer, the companies said today.

CompanionDx will use GenomOncology's GO Clinical Workbench software to develop a clinical report from the raw sequencing data.

The GO Clinical Workbench analysis is fully traceable and includes a decision support tool for the interpretation of somatic mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.